Apolipoprotein E regulates primary cultured human mesangial cell proliferation

Nephron - Experimental Nephrology

Volumn 102, Issue 2, 2006, Pages

  Zhang, Yixiang ^a   Yasumoto, Yuichiro ^a   Ikeda, Toru ^c   Takenouchi, Syozo ^a   Sogabe, Atsushi ^a   Nosaki, Tsuyoshi ^a   Che, Xiaofang ^b   Zheng, Chunlei ^b   Haraguchi, Misako ^b   Akiyama, Shin Ichi ^b   Tsubouchi, Hirohito ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c Ikeda Hospital   (Japan)

Author keywords

Apolipoprotein B; Apolipoprotein E; Apoptosis; Cell cycle; DNA stain; Flow cytometer; Human mesangial cell; Isoforms; Proliferation; WST 1

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ISOPROTEIN;

APOPTOSIS; ARTICLE; ASSAY; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MESANGIUM CELL; PRIORITY JOURNAL;

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS B; APOLIPOPROTEINS E; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DRUG COMBINATIONS; GLOMERULAR MESANGIUM; HUMANS; TIME FACTORS;

EID: 30644476818     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088402     Document Type: Article

References (23)

1. Saito T: Abnormal lipid metabolism and renal disorders. Tohoku J Exp Med 1997;181:321-337.
2. Grone EF, Abboud HE, Hohne M, Walli AK, Grone HJ, Stuker D, Robenek H, Wieland E, Seidel D: Actions of lipoproteins in cultured human mesangial cells: modulation by mitogenic vasoconstrictors. Am J Physiol 1992;263:F686-F696.
3. Inoue CN: LPA as a determinant of mesangial growth and apoptosis. Semin Nephrol 2002;22:415-422.
4. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, Schoolwerth AC: PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003;64:52-62.
5. Kolovou G, Daskalova D, Mikhailidis DP: Apolipoprotein E polymorphism and atherosclerosis. Angiology 2003;54:59-71.
6. Bocksch L, Stephens T, Lucas A, Singh B: Apolipoprotein E: possible therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2001;1:93-106.
7. Mahley RW, Huang Y, Rall SC Jr: Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933-1949.
8. Shibata T, Kaneko N, Hara Y, Saito T, Sakaguchi H: A case of lipoprotein glomerulopathy: light and electron microscopic observations of the glomerulus. Acta Pathol Jpn 1990;40:448-457.
9. Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Arakawa M: Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apo B and apo E. Clin Nephrol 1991;36:127-133.
10. Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, Kodama T, Suzuki H, Maki S: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993;43:918-927.
11. van Goor H, van der Horst ML, Atmosoerodjo J, Joles JA, van Tol A, Grond J: Renal apolipoproteins in nephrotic rats. Am J Pathol 1993;142:1804-1812.
12. Bruneval P, Bariety J, Belair MF, Mandet C, Heudes D, Nicoletti A: Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apo E null mice. Nephrol Dial Transplant 2002;17:2099-2107.
13. Tenger C, Zhou X: Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. Immunology 2003;109:392-397.
14. Bocksch L, Stephens T, Lucas A, Singh B: Apolipoprotein E: Possible therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2001;1:93-106.
15. Grone EF, Walli AK, Grone HJ, Miller B, Seidel D: The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994;107:1-13.
16. Liberopoulos E, Siamopoulos K, Elisaf M: Apolipoprotein E and renal disease. Am J Kidney Dis 2004;43:223-233.
17. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S: A protective role for kidney apolipoprotein E: regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 2001;276:49142-49147. Epub 2001 Sep 28.
18. Chowdhury TA, Dyer PH, Kumar S, Gibson SP, Rowe BR, Davies SJ, Marshall SM, Morris PJ, Gill GV, Feeney S, Maxwell P, Savage D, Boulton AJ, Todd JA, Dunger D, Barnett AH, Bain SC: Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes 1998;47:278-280.
19. Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, Nomura M, Abiko A, Iwashima Y, Ikoda A, et al: Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 1995;48:288-292.
20. Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K: Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002;40:243-251.
21. Liberopoulos E, Siamopoulos K, Elisaf M: Apolipoprotein E and renal disease. Am J Kidney Dis 2004;43:223-233.
22. Walldius G, Jungner I: Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188-205.
23. Ohtani H, Matoba K, Saika Y, Tanaka R, Yamada Y, Bando K, Takahashi T, Mune M, Yukawa S, Nomoto H: Glomerular apolipoprotein B deposition in glomerular diseases. Nippon Jinzo Gakkai Shi 1990;32:1145-1152.